Related Experiment Videos
Bone lesions in malignant diseases--II. Therapeutic management
Stescho E Goranov1, Simeon B Simeonov
1Clinic of Hematology, Clinic of Endocrinology and Mineral Metabolism, Medical University, St Georgi Hospital, Plovdiv, Bulgaria.
Abstract:
A pathogenetically based therapeutic strategy and modality for malignant bone diseases has been created only in the last two decades. The most frequent pathogenetic defect, osteoblast/osteoclast uncoupling in the osteolytic foci and the diffuse humoral osteoporosis afford little in terms of choice of treatment which makes the inhibitors of osteoclastic activity the major medicamentous agents for their management. We discuss the mechanisms of action, pharmacokinetics, preparations and regimens of administration of biphosphonates, calcitonine and galium nitrate. Results of large double blind, placebo-controlled studies of clondronate and pamidronate in oncohematologic diseases are summarised: statistically significantly lower frequency of the osteolytic foci, pathological fractures, hypercalcemic episodes, low levels of C-L bonds, increase of bone mineral density, management of pain, and better quality of life.
Insights
New treatments for malignant bone diseases focus on inhibiting osteoclasts. Biphosphonates and other agents show significant benefits, reducing bone lesions, fractures, and improving patient quality of life.
Area of Science:
- Oncology
- Orthopedics
- Pharmacology
Background:
- Malignant bone diseases present limited therapeutic options due to osteoblast/osteoclast uncoupling and osteoporosis.
- Inhibitors of osteoclastic activity are the primary medical agents for managing these conditions.
Purpose of the Study:
- To review therapeutic strategies for malignant bone diseases, focusing on osteoclast inhibition.
- To discuss the mechanisms, pharmacokinetics, and administration of key drugs like biphosphonates, calcitonin, and gallium nitrate.
Main Methods:
- Review of existing literature and large double-blind, placebo-controlled studies.
- Analysis of therapeutic outcomes for clondronate and pamidronate in oncohematologic diseases.
Main Results:
- Clondronate and pamidronate significantly reduced osteolytic lesions and pathological fractures.
- These treatments led to fewer hypercalcemic episodes and improved bone mineral density.
- Patients experienced better pain management and enhanced quality of life.
Conclusions:
- Osteoclast inhibitors represent a key therapeutic advance for malignant bone diseases.
- Biphosphonates, such as clondronate and pamidronate, demonstrate efficacy in improving clinical outcomes and patient well-being.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy